BridgeMD
Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome
EU CTIS ID: 2024-518001-18-00
What this study is testing
1. Clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in Turner syndrome after a washout period. 2. Compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome. 3. Examine the long-term effects of ERT via the two routes on endocrine, metabolic, cardiovascular, physiological, and thromboembolic risk endpoints.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of Turner syndrome regardless of karyotype (Turner syndrome)
- Age 18-50 years (Turner syndrome and healthy controls)
- Already receiving estrogen treatment (Turner syndrome)
- Female (healthy controls)
- Previously healthy (healthy controls)
- Not receiving any medication (healthy controls)
You likely can't join if
- Active systemic chronic diseases
- Known or suspected breast cancer
- Known or suspected estradiol-dependent tumors (endometrial cancer or similar)
- Untreated endometrial hyperplasia
- Current or previous venous thromboembolism
- Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more
See the full eligibility criteria
- Diagnosis of Turner syndrome regardless of karyotype (Turner syndrome)
- Age 18-50 years (Turner syndrome and healthy controls)
- Already receiving estrogen treatment (Turner syndrome)
- Female (healthy controls)
- Previously healthy (healthy controls)
- Not receiving any medication (healthy controls)
- Not using any form of contraceptive pills (healthy controls)
- No mental or psychiatric disorders (healthy controls)
- Active systemic chronic diseases
- Known or suspected breast cancer
- Known or suspected estradiol-dependent tumors (endometrial cancer or similar)
- Untreated endometrial hyperplasia
- Current or previous venous thromboembolism
- Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more
- Known hypersensitivity to the medications used
- Pregnancy
- Menopause (healthy controls only)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.